1052. Serologic vs. molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies with and without prior hematopoietic cell transplant recipients

BACKGROUND: The prevalence of chronic hepatitis C virus (HCV) infection in patients with cancer in the U.S. has been reported to be 1.5% overall and up to 10.6% in specific subgroups. Testing for antibody to HCV (anti-HCV) is a low-cost diagnostic method in widespread use worldwide; however, the opt...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, Harrys A, Angelidakis, Georgios, Jiang, Ying, Economides, Minas, Yibirin, Marcel, MD, Robert Orlowski, Champlin, Richard, Verstovsek, Srdan, Raad, Issam I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777433/
http://dx.doi.org/10.1093/ofid/ofaa439.1238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777433/
http://dx.doi.org/10.1093/ofid/ofaa439.1238

Ejemplares similares